Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis
Status:
Completed
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to investigate the efficacy and safety of oral
antimycobacterial therapy in patients with confirmed progressive pulmonary sarcoidosis. We
suspect that the CLEAR regimen will improve the absolute FVC percent predicted in chronic
pulmonary sarcoidosis participants.